QL1A Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Ex-China GrowthBroad growth outside China shows resilient demand across core diagnostic franchises and reduces dependence on one geography. Continued expansion in labs, immunohematology and point-of-care testing supports a more diversified revenue base.
EBITDA Margin ExpansionStrong EBITDA growth and margin expansion indicate operating leverage and improving cost discipline despite a seasonally weak quarter. If sustained, the improvement can strengthen profitability and support management’s longer-term cash-conversion efforts.
Recurring Consumables ModelConsumables linked to installed analyzers create repeat revenue as customers run tests, while broader menus can increase utilization. This model provides durable customer relationships and recurring demand beyond one-time instrument placements.
Bears Say
Persistent Profitability WeaknessLarge losses combined with limited recent revenue growth indicate that the cost structure remains a major constraint. Sustained negative profitability can consume capital, weaken returns and limit the company’s ability to invest or reduce debt.
Negative Cash GenerationNegative operating and free cash flow show that the business is currently consuming rather than generating cash. Withdrawal of guidance also signals limited visibility, increasing dependence on working-capital improvement and disciplined spending.
China And Leverage RiskRegulatory pricing uncertainty is weakening a major market while elevated leverage reduces financial flexibility. Prolonged China pressure could impair cash generation and make deleveraging harder, increasing execution risk during the turnaround.
QuidelOrtho News
QL1A FAQ
What was QuidelOrtho’s price range in the past 12 months?
Currently, no data Available
What is QuidelOrtho’s market cap?
QuidelOrtho’s market cap is CHF811.71M.
When is QuidelOrtho’s upcoming earnings report date?
QuidelOrtho’s upcoming earnings report date is Nov 04, 2026 which is in 77 days.
How were QuidelOrtho’s earnings last quarter?
QuidelOrtho released its earnings results on Aug 06, 2026. The company reported CHF0.106 earnings per share for the quarter, beating the consensus estimate of -CHF0.04 by CHF0.146.
Is QuidelOrtho overvalued?
According to Wall Street analysts QuidelOrtho’s price is currently Undervalued.
Does QuidelOrtho pay dividends?
QuidelOrtho does not currently pay dividends.
What is QuidelOrtho’s EPS estimate?
QuidelOrtho’s EPS estimate is 0.17.
How many shares outstanding does QuidelOrtho have?
Currently, no data Available
What happened to QuidelOrtho’s price movement after its last earnings report?
QuidelOrtho reported an EPS of CHF0.106 in its last earnings report, beating expectations of -CHF0.04. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of QuidelOrtho?
Currently, no hedge funds are holding shares in CH:QL1A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
QuidelOrtho Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
CHF12.18 (― Upside)
CHF12.18 (― Upside)
Blogger Sentiment
Neutral
CH:QL1A Sentiment 60%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.04%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.41%
Trailing 12-Months
Company Description
QuidelOrtho
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
QL1A Company Deck
QL1A Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a mixed picture: solid underlying operational performance outside China (mid-single-digit growth ex-China, strong regional results, 21% YoY adjusted EBITDA growth, and margin expansion) and tangible progress on the Lex/Neulixa commercialization. Offsetting these positives were significant near-term headwinds — a 23% revenue decline in China driven by IVD pricing uncertainty, a softer respiratory season, negative operating and free cash flow in the quarter, withdrawal of free-cash-flow guidance, and elevated leverage (4.3x). Management emphasized disciplined cost actions, cash-conversion priorities, and mitigation plans, but the combination of China uncertainty and weak respiratory demand creates meaningful short-term risk even as core franchises remain resilient.View all CH:QL1A earnings summaries